Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Restructuring Costs (2023 - 2025)

BioXcel Therapeutics has reported Restructuring Costs over the past 3 years, most recently at $194000.0 for Q3 2025.

  • Quarterly results put Restructuring Costs at $194000.0 for Q3 2025, down 87.51% from a year ago — trailing twelve months through Dec 2025 was $227000.0 (down 90.7% YoY), and the annual figure for FY2025 was $194000.0, down 92.05%.
  • Restructuring Costs for Q3 2025 was $194000.0 at BioXcel Therapeutics, up from $33000.0 in the prior quarter.
  • Over the last five years, Restructuring Costs for BTAI hit a ceiling of $4.2 million in Q3 2023 and a floor of $33000.0 in Q4 2024.
  • Median Restructuring Costs over the past 3 years was $856000.0 (2024), compared with a mean of $1.4 million.
  • Biggest five-year swings in Restructuring Costs: tumbled 62.7% in 2024 and later crashed 87.51% in 2025.
  • BioXcel Therapeutics' Restructuring Costs stood at $4.2 million in 2023, then crashed by 99.21% to $33000.0 in 2024, then soared by 487.88% to $194000.0 in 2025.
  • The last three reported values for Restructuring Costs were $194000.0 (Q3 2025), $33000.0 (Q4 2024), and $1.6 million (Q3 2024) per Business Quant data.